89zr df-iab2m
mAbexperimentalImaging agent
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01923727)
Timeline
Indications
Mechanism of action
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 89-zirconium
Oral
No
Parenteral
No
Topical
No
Also known as
- 89zr-df-iab22m2c
- 89zr df-iab2m
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03107663 | Phase 1 | Apr 1, 2017 | Cornell University, ImaginAb, Inc. |
| NCT02424513 | Phase 2 | Mar 1, 2015 | Cornell University, ImaginAb, Inc. |
| NCT02349022 | Phase 2 | Jan 1, 2015 | ImaginAb, Inc. |
| NCT01923727 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2013 | Cornell University, ImaginAb, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImaginAb, Inc. | For profit | 4 | 4 | 2 | 2013 |
| Cornell University | Academic/Hospital | 3 | 0 | 2 | 2013 |
2 organizations
Page 1 / 1